CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,301 | -26.3% | 1,681 | -8.8% | 0.05% | -24.6% |
| Q2 2023 | $103,522 | +13.5% | 1,844 | -8.6% | 0.06% | +22.0% |
| Q1 2023 | $91,229 | -19.6% | 2,017 | -27.7% | 0.05% | -15.3% |
| Q4 2022 | $113,454 | -3.0% | 2,791 | +55.5% | 0.06% | +25.5% |
| Q3 2022 | $117,000 | +8.3% | 1,795 | +0.6% | 0.05% | +17.5% |
| Q2 2022 | $108,000 | -17.6% | 1,784 | -14.3% | 0.04% | -32.2% |
| Q1 2022 | $131,000 | -21.6% | 2,081 | -5.5% | 0.06% | -6.3% |
| Q4 2021 | $167,000 | -9.2% | 2,203 | +34.0% | 0.06% | -22.2% |
| Q3 2021 | $184,000 | -34.5% | 1,644 | -5.4% | 0.08% | -30.2% |
| Q2 2021 | $281,000 | +15.2% | 1,737 | -13.3% | 0.12% | +12.6% |
| Q1 2021 | $244,000 | -18.9% | 2,003 | +1.9% | 0.10% | -17.6% |
| Q4 2020 | $301,000 | -30.2% | 1,966 | -61.9% | 0.12% | -44.7% |
| Q3 2020 | $431,000 | +0.5% | 5,155 | -11.8% | 0.23% | +11.3% |
| Q2 2020 | $429,000 | +84.1% | 5,844 | +6.3% | 0.20% | +111.5% |
| Q1 2020 | $233,000 | -39.3% | 5,497 | -12.8% | 0.10% | +52.4% |
| Q4 2019 | $384,000 | – | 6,306 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |